A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.
Arthur S WaldbaumJane R SchwebkeJeremy R A PaullClare F PriceStephanie R EdmondsonAlex CastellarnauPhilip McCloudGeorge R KinghornPublished in: PloS one (2020)
Astodrimer Gel once daily for 7 days was superior to placebo for treatment of bacterial vaginosis and was well-tolerated. The 1% dose consistently showed the strongest efficacy across endpoints. These results support a role for Astodrimer Gel, 1%, as an effective treatment for bacterial vaginosis.